The company will begin Phase II trials of ISIS 104838, administered intravenously and subcutaneously, in patients with RA this year. Isis will initiate clinical trials of topically administered ISIS 104838 in patients with psoriasis by mid-year. Oral formulations of ISIS 104838 will advance into the clinic by the end of the year. ISIS 104838 is the subject of our collaboration with Elan to establish a platform technology for oral delivery. Isis plans to initiate a Phase I trial in late 2001.
Preclinical data demonstrate compelling activity in multiple diabetic animal models.
As a second-generation product, its improved chemistry will allow for a more convenient dosing schedule. To date, the company has over issued or allowed 700 patents covering antisense technology and RNA-based drug discovery. Isis' compounds in development and corporate partnerships. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Actual results could differ materially from those projected in this Fact Sheet.